| Previous Close | 37.72 |
| Open | 37.94 |
| Bid | 38.08 x 1200 |
| Ask | 38.14 x 800 |
| Day's Range | 37.89 - 38.18 |
| 52 Week Range | 30.99 - 53.40 |
| Volume | 92,848 |
| Avg. Volume | 220,482 |
| Market Cap | 23.097B |
| Beta (3Y Monthly) | 1.93 |
| PE Ratio (TTM) | 10.31 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.63 (1.50%) |
| Ex-Dividend Date | 2019-05-17 |
| 1y Target Est | N/A |
Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (“Fresenius” or the “Company”) (NYSE: FMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
NEW YORK, NY / ACCESSWIRE / April 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (''Fresenius'' or the ''Company'') (FMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Fresenius and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (“Fresenius” or the “Company”) (NYSE: FMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
WALTHAM, Mass., Feb. 26, 2019 /PRNewswire/ -- Fresenius Medical Care, the world's largest provider of dialysis products and services, has successfully completed the acquisition of NxStage Medical, Inc. (NxStage), following approval by antitrust authorities in the United States. NxStage develops, produces and markets an innovative product portfolio of medical devices for use in home dialysis and critical care. The acquisition will enable Fresenius Medical Care to leverage its manufacturing, supply chain and marketing competencies across the dialysis products, services and Care Coordination businesses in a less labor- and capital-intensive care setting.
BAD HOMBURG, GERMANY / ACCESSWIRE / February 21, 2019 / Fresenius Medical Care, the world's largest provider of dialysis products and services, announced that it has filed the annual report 2018 under ...
MONMOUTH JUNCTION, N.J., Jan. 22, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced today that it has expanded its partnership with Fresenius Medical Care to Korea and Mexico. Under the terms of the agreement, Fresenius Medical Care has the exclusive rights to distribute CytoSorb for acute care and other hospital applications in Korea and Mexico.
NEW YORK, Nov. 20, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
RICHMOND, Va. , Nov. 1, 2018 /PRNewswire/ -- Capital Square 1031, a leading sponsor of Delaware statutory trust investments, announced today that CS1031 Diversified Dialysis Portfolio, DST, comprised of ...
NEW YORK, NY / ACCESSWIRE / October 18, 2018 / Oragenics was gaining on Wednesday after announcing it has received clearance to enroll patients into a Phase 2 clinical trial. Shares of Fresenius Medical Care were deep in the red as traders digested the company’s slashed guidance for the third quarter. Fresenius Medical Care AG & Co. KGaA shares closed down nearly 17% on about 1.1 million shares traded yesterday.
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Fresenius Medical Care AG & Co. KGaA (NYSE: FMS ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 3:30 PM ...
BOSTON, June 11, 2018 /PRNewswire/ -- Fresenius Medical Care, the world's largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, today announced a strategic, global partnership and a $150M USD equity investment. This agreement has the potential to make Humacyte's investigational human acellular vessel, HUMACYL®, available to more patients worldwide following approval of the product. HUMACYL is currently being investigated for vascular access for hemodialysis and may prove more effective than current synthetic grafts and fistula.